Is PTC Stock a Buy, Sell or Hold?
PTC (NASDAQ:PTC) is a maker of product lifecycle management software…
Sell
24
CATX Quote, Financials, Valuation and Earnings
Last price:
$2.64
Seasonality move
:
15.2%
Day range:
$2.61 - $2.82
52-week range:
$2.32 - $19.05
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
14.09x
P/B ratio:
0.54x
Volume:
466.5K
Avg. volume:
708.2K
1-year change:
-75.38%
Market cap:
$176.4M
Revenue:
--
EPS (TTM):
-$1.46
Analysts' Opinion
-
Consensus RatingPerspective Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.50, Perspective Therapeutics has an estimated upside of 532.18% from its current price of $2.61.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing -129.89% downside risk from its current price of $2.61.
Fair Value
-
According to the consensus of 10 analysts, Perspective Therapeutics has 532.18% upside to fair value with a price target of $16.50 per share.
CATX vs. S&P 500
-
Over the past 5 trading days, Perspective Therapeutics has underperformed the S&P 500 by -3.12% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Perspective Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Perspective Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Perspective Therapeutics reported revenues of --.
Earnings Growth
-
Perspective Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Perspective Therapeutics reported earnings per share of -$0.21.
Enterprise value:
-89.8M
EV / Invested capital:
--
Price / LTM sales:
14.09x
EV / EBIT:
--
EV / Revenue:
-9.02x
PEG ratio (5yr expected):
-0.22x
EV / Free cash flow:
2.21x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $9.9M | $7M | -- | $1.9M | -- | |
| Gross Profit | $4M | -- | -- | -- | -- | |
| Operating Income | -$9.3M | -$33.5M | -$57.6M | -$9.8M | -$18.6M | |
| EBITDA | -$9.1M | -$31.9M | -$47.8M | -$9.3M | -$14.4M | |
| Diluted EPS | -$0.60 | -$1.07 | -$1.46 | -$0.37 | -$0.21 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $4.7M | $65M | $57.5M | $21.7M | $270.2M | |
| Total Assets | $8M | $68.7M | $62.5M | $110.5M | $391.2M | |
| Current Liabilities | $1.5M | $1.8M | $4M | $8.1M | $28.1M | |
| Total Liabilities | $2.9M | $3M | $4.8M | $11.7M | $62.7M | |
| Total Equity | $5.1M | $65.8M | $57.7M | $98.8M | $328.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7.4M | -$29.7M | -$696K | -$10.1M | $3.4M | |
| Cash From Investing | -$35.4M | -$10.7M | -$80.4M | -$227K | -$29.7M | |
| Cash From Financing | $84K | $461K | $289.4M | $1K | $628K | |
| Free Cash Flow | -$7.7M | -$30.7M | -$40.6M | -$10.3M | -$26.3M | |
CATX
Sector
Market Cap
$176.4M
$38.8M
Price % of 52-Week High
13.7%
46.15%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-75.38%
-38.89%
Beta (5-Year)
1.251
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$2.59
200-day SMA
Sell
Level
$9.34
Bollinger Bands (100)
Sell
Level
1.87 - 9.29
Chaikin Money Flow
Sell
Level
-324.9M
20-day SMA
Sell
Level
$2.82
Relative Strength Index (RSI14)
Sell
Level
40.03
ADX Line
Sell
Level
32.61
Williams %R
Neutral
Level
-63.2911
50-day SMA
Sell
Level
$3.20
MACD (12, 26)
Sell
Level
-0.24
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
528.8M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
Stock Forecast FAQ
In the current month, CATX has received 9 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CATX average analyst price target in the past 3 months is $16.50.
-
Where Will Perspective Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Perspective Therapeutics share price will rise to $16.50 per share over the next 12 months.
-
What Do Analysts Say About Perspective Therapeutics?
Analysts are divided on their view about Perspective Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Perspective Therapeutics is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Perspective Therapeutics's Price Target?
The price target for Perspective Therapeutics over the next 1-year time period is forecast to be $16.50 according to 10 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is CATX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Perspective Therapeutics is a Buy. 9 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CATX?
You can purchase shares of Perspective Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Perspective Therapeutics shares.
-
What Is The Perspective Therapeutics Share Price Today?
Perspective Therapeutics was last trading at $2.64 per share. This represents the most recent stock quote for Perspective Therapeutics. Yesterday, Perspective Therapeutics closed at $2.61 per share.
-
How To Buy Perspective Therapeutics Stock Online?
In order to purchase Perspective Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Stocks Have Largest Share Buybacks Now?
In February 2025 alone, over 160 companies announced new buyback…
Is Disney Stock a Bargain After Recent Challenges?
All is not well with entertainment behemoth The Walt Disney…
Stock Ideas
Buy
62
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
86
WLDN alert for Mar 8
Willdan Group [WLDN] is up 29.67% over the past day.
Buy
76
PDEX alert for Mar 8
Pro-Dex [PDEX] is up 19.69% over the past day.
Sell
7
IOT alert for Mar 8
Samsara [IOT] is down 15.54% over the past day.
